Fatma Kaplan, Ph.D. is the CEO of Pheronym, Inc. She has a Ph.D. in plant molecular stress biology and postdoc in chemistry and social behavior of nematodes which are the most abundant animals on earth. They parasitize nearly every species such as plants, insect and humans. Dr. Kaplan was the first to isolate sex pheromone of nematode, Caenorhabditis elegans, discovered that the same class of pheromones controlled both development and behavior, published in Nature 2008. Then, she found agriculturally important nematodes use the same class of pheromones for nematode behavior at the United States Department of Agriculture and published in PLoS One in 2012. Pheromone technology has practical applications to control parasitic nematodes for food security and drug development. Dr. Kaplan co-founded Pheronym to turn pheromone technology into a product and provide effective pest control to farmers, growers, and homeowners.
Did you know?
While it might look like a plant-based food company, NotCo is in the data and AI business—and aims to disrupt R&D in many industries that use animal and plant ingredients.
Gilberto Loureiro grew up inspecting fabrics in a Portuguese textile factory. With Smartex, he and co-founders Antonio Rocha and Paulo Ribeiro are eliminating textile defects—and their enormous cost both to manufacturers and the environment.
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.